Jubilant Ingrevia has successfully acquired a 100% equity stake in Remidex Pharma Private Limited. This acquisition was completed as per the Share Purchase Agreement previously announced by the company. The transaction details were initially disclosed in a letter dated March 13, 2026, and the acquisition was finalised on March 30, 2026.
The acquisition aligns with Jubilant Ingrevia‘s strategic objectives and marks a significant step in expanding its pharmaceutical capabilities. The company had earlier communicated the key terms of the transaction to the stock exchanges, ensuring transparency and compliance with regulatory requirements.
The information regarding the acquisition has been made available on Jubilant Ingrevia’s official website, providing stakeholders with access to the detailed documentation. This move is expected to enhance Jubilant Ingrevia’s market presence and operational capabilities within the pharmaceutical sector.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).